title: [Congestive heart failure: Treatment with ultrafiltration].
abstract: BACKGROUND
  The prevalence rate of congestive heart failure is approximately 2% in high-income countries. The aim of this study was to assess the overall benefit of ultrafiltration therapy in patients with acute or persistent congestive heart failure.
  
  
  METHODS
  We conducted a health technology assessment following the EUnetHTA guidelines, with systematic literature review from bibliographic medical databases, independent experts and manufacturer interviews.
  
  
  RESULTS
  Thirteen clinical trials and five meta-analyses were examined. In the most recent one, 608 patients were included, of which 304 received ultrafiltration therapy and 304 received intravenous loop diuretics. Ultrafiltration therapy seems to be more beneficial regarding the fluid removal and the body weight reduction, (mean difference respectively 1.44kg, IC95% [0.29; 2.59], P-value=0.01 and 1.28L [0.43; 2.12], P-value=0.003). No difference has been showed in overall mortality, renal function, hospital readmission or safety. Medico-economic studies are incomplete and contradictory.
  
  
  CONCLUSIONS
  Ultrafiltration therapy seems to be effective, most likely for patients ineligible or resistant to intravenous diuretics. But most topics remain uncertain, mainly impact on overall mortality, safety and cost-effectiveness. Given these knowledge-gaps, the generalization of ultrafiltration therapy should be examined cautiously, and conditional upon a large-scale systematic evaluation.
authors.affiliation: Comité d'évaluation et de diffusion des innovations technologiques (CEDIT), AP-HP, 3, avenue Victoria, 75004 Paris, France. Electronic address: c.taron.brocard@gmail.com.
authors.forename: C
authors.initials: C
authors.lastname: Taron-Brocard
authors.affiliation: Comité d'évaluation et de diffusion des innovations technologiques (CEDIT), AP-HP, 3, avenue Victoria, 75004 Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Looten
authors.affiliation: Comité d'évaluation et de diffusion des innovations technologiques (CEDIT), AP-HP, 3, avenue Victoria, 75004 Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Fahlgren
authors.affiliation: Comité d'évaluation et de diffusion des innovations technologiques (CEDIT), AP-HP, 3, avenue Victoria, 75004 Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Charpentier
authors.affiliation: Comité d'évaluation et de diffusion des innovations technologiques (CEDIT), AP-HP, 3, avenue Victoria, 75004 Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Guillevin
authors.affiliation: Comité d'évaluation et de diffusion des innovations technologiques (CEDIT), AP-HP, 3, avenue Victoria, 75004 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Barna
mesh_terms: D001835:Body Weight; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000628:therapy*; D006440:Hemofiltration; D006801:Humans; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000627:therapeutic use
chemical_list: D049994:Sodium Potassium Chloride Symporter Inhibitors
keywords: Aquapheresis; Aquaphérèse; Congestive heart failure; Hemofiltration; Hémofiltration; Insuffisance cardiaque congestive; Renal replacement therapy; Ultrafiltration; Épuration extra-rénale